{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:10:39Z","timestamp":1778767839516,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.trecan.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:52:58Z","timestamp":1773147178000},"page":"390-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL33 in pancreatic cancer\u2014pro- or antitumor?"],"prefix":"10.1016","volume":"12","author":[{"given":"Supriya","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.01.009_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2026.01.009_bb0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2026.01.009_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155891","article-title":"Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine","volume":"156","author":"Cayrol","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.trecan.2026.01.009_bb0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cyto.2012.06.286","article-title":"Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells","volume":"60","author":"Schmieder","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.trecan.2026.01.009_bb0025","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41586-020-03147-x","article-title":"A gene-environment-induced epigenetic program initiates tumorigenesis","volume":"590","author":"Alonso-Curbelo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.01.009_bb0030","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41467-024-48441-8","article-title":"Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression","volume":"15","author":"Park","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.01.009_bb0035","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/cancers17132087","article-title":"Tropisetron suppresses chronic pancreatitis and pancreatic cancer by blocking interleukin 33 expression","volume":"1713","author":"Bae","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2026.01.009_bb0040","article-title":"Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis","volume":"320","author":"Andersson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.01.009_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccell.2022.01.003","article-title":"Fungal mycobiome drives -33 secretion and type 2 immunity in pancreatic cancer","volume":"40","author":"Alam","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.01.009_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12032-016-0880-3","article-title":"IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer","volume":"34","author":"Fang","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.trecan.2026.01.009_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-018-1223-3","article-title":"Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy","volume":"36","author":"Kieler","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.trecan.2026.01.009_bb0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","article-title":"ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity","volume":"579","author":"Moral","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.01.009_bb0065","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","article-title":"IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer","volume":"638","author":"Amisaki","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.01.009_bb0070","article-title":"Targeting TNF-\u03b1-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling","volume":"722","author":"Dixit","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.01.009_bb0075","doi-asserted-by":"crossref","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat. Commun."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:21:10Z","timestamp":1778764870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2405803326000221"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.009","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL33 in pancreatic cancer\u2014pro- or antitumor?","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}